Peripheral neuropathy (PN) and asthenia (fatigue) are among the most commonly seen complications in patients undergoing multiple myeloma (MM) therapy. These potentially debilitating adverse effects are frequently dose limiting, and they may
Search Results
Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades, and Kenneth Anderson
Andrea Angelo Martoni, Luigi Cavanna, and Gianpiero Porzio
Re: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw 2017
Ann M. Berger and Kathi Mooney
Evidence-based recommendations for cancer-related fatigue (CRF) have been disseminated recently by all major cancer organizations (NCCN, Oncology Nursing Society [ONS], Canadian Partnership Against Cancer/Canadian Association of Psychosocial
John A. Glaspy
anemic cancer patients when referenced to the general population . J Clin Oncol 2003 ; 21 : 366 – 373 . 2 Cella D Kallich J McDermott A Xu X . The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer
John A. Glaspy
X . The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials . Ann Oncol 2004 ; 15 : 979 – 986 . 6. Berndt E Kallich J McDermott A . Reductions in
Romy M. van Amelsfoort, Iris Walraven, Jacobien Kieffer, Edwin P.M. Jansen, Annemieke Cats, Nicole C.T. van Grieken, Elma Meershoek-Klein Kranenbarg, Hein Putter, Johanna W. van Sandick, Karolina Sikorska, Cornelis J.H. van de Velde, Neil K. Aaronson, Marcel Verheij, and on behalf of the CRITICS Investigators
functioning, role functioning, cognitive functioning, emotional functioning, and social functioning), 3 multi-item symptom scales (fatigue, nausea and vomiting, and pain), 6 single-item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea
Tara M. Mackay, Anouk E.J. Latenstein, Mirjam A.G. Sprangers, Lydia G. van der Geest, Geert-Jan Creemers, Susan van Dieren, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y.V. Homs, Evelien J.M. de Jong, I. Quintus Molenaar, Gijs A. Patijn, Lonneke V. van de Poll-Franse, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W.M. van Laarhoven, and for the Dutch Pancreatic Cancer Group
cancer-specific EORTC QLQ-C30 questionnaire encompasses global health status, 5 functioning scales (ie, physical, role, emotional, cognitive, and social functioning) and 8 symptom scales/items (ie, fatigue, nausea and vomiting, pain, dyspnea, insomnia
Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass
parasomnias. 1 Sleep disorders affect 30% to 50% of patients with cancer and survivors, often in combination with fatigue, anxiety, or depression. 1 - 10 Improvements in sleep lead to improvements in fatigue, mood, and quality of life. 11 Most clinicians
Christina Teng, Venkatesha, Prunella L. Blinman, and Janette L. Vardy
discontinuation of oxaliplatin. Abbreviation: PN, peripheral neuropathy. a Nausea (n=1), fatigue (n=1), vomiting (n=1), bleeding (n=1), thrombophlebitis (n=1), de-escalated due to clinical trial (n=2). Burden of PN Single Item Score of Numbness and
Sriman Swarup, Anita Sultan, Nusrat Jahan, Upama Sharma, Nimesh Adhikari, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein
treated with cabozantinib. Methods: We systematically conducted a comprehensive literature search using MEDLINE, EMBASE databases, and meeting abstracts through September 30, 2018. Phase 3 trials that mention HRQOL events like pain, arthralgia, fatigue
